1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Cancer Diagnostics Market by Technology, Application - Forecast to 2020

According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

The instrument-based cancer diagnostics segment accounted for the largest share of the global the cancer diagnostics market, by technology, while breast cancer accounted for the largest share of the cancer diagnostics applications market, in 2014.
North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.

The global cancer diagnostics market witnesses high competitive intensity as there are several big and many small firms operating in different segments of the market. These companies adopt various strategies (agreements/partnerships/joint ventures/collaborations, new product launches, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cancer diagnostics market. The report analyzes cancer diagnostics by technology, application, and geography

- Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cancer diagnostics market

- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cancer diagnostic technologies across regions

- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the cancer diagnostics market

- Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the cancer diagnostics market

Table Of Contents

Cancer Diagnostics Market by Technology, Application - Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1.1 RESEARCH METHODOLOGY STEPS 22
2.1.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
2.1.2.1 Secondary Research 23
2.1.3 KEY DATA FROM SECONDARY SOURCES 23
2.1.3.1 Primary research 24
2.1.3.2 Key industry insights 24
2.1.4 KEY DATA FROM PRIMARY SOURCES 25
2.1.5 KEY INSIGHTS FROM PRIMARY SOURCES 26
2.1.6 MARKET SIZE ESTIMATION METHODOLOGY 26
2.1.7 RESEARCH DESIGN 28
2.1.8 MARKET DATA VALIDATION AND TRIANGULATION 28
2.1.9 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CURRENT SCENARIO 31
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 33
4 PREMIUM INSIGHTS 34
4.1 GLOBAL CANCER DIAGNOSTICS MARKET 34
4.2 REGIONAL SNAPSHOT OF THE CANCER DIAGNOSTICS MARKET 36
4.3 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2015 VS. 2020) 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
?
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 39
5.2.1.1 Rising prevalence of cancer 39
5.2.1.2 Technological Advancements 39
5.2.1.3 Initiatives undertaken by governments and global health organizations to spread awareness about cancer 39
5.2.1.4 Growth in the number of private diagnostic centers 40
5.2.1.5 Public-private partnerships to enhance the infrastructure of diagnostic imaging centers 40
5.2.1.6 FDA support for biomarker development 41
5.2.1.7 Launch of new flow cytometry reagents for diagnostics and drug discovery 41
5.2.2 RESTRAINTS 43
5.2.2.1 High capital investments and low benefit-cost ratio for biomarkers 43
5.2.2.2 Shortage of helium 43
5.2.2.3 High cost of diagnostic imaging systems affecting their rate of adoption in emerging markets 43
5.2.2.4 Risk of high radiation exposure likely to limit the usage of CT scanners 44
5.2.2.5 Dearth of skilled and experienced personnel 44
5.2.3 OPPORTUNITIES 46
5.2.3.1 Personalized medicine 46
5.2.3.2 Development of mass cytometry and the combination of cell-and bead-based flow cytometry technologies 46
5.2.3.3 Companion Diagnostics 47
5.2.3.4 Improving healthcare infrastructure in emerging markets 47
5.2.3.5 Miniaturized and technologically advanced devices 48
5.2.4 CHALLENGES 49
5.2.4.1 Stringent regulatory guidelines 49
5.2.4.2 Hospital budget cuts a key challenge to market players 50
5.2.4.3 Increasing adoption of refurbished diagnostic imaging systems 50
6 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION 52
6.1 INTRODUCTION 53
6.1.1 BREAST CANCER 55
6.1.2 LUNG CANCER 56
6.1.3 COLORECTAL CANCER 57
6.1.4 MELANOMA 58
6.1.5 OTHER CANCERS 59
7 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 61
7.1 INTRODUCTION 62
?
7.2 PLATFORM-BASED DIAGNOSTICS 63
7.2.1 POLYMERASE CHAIN REACTION (PCR) 64
7.2.2 IN SITU HYBRIDIZATION (ISH) 66
7.2.3 IMMUNOHISTOCHEMISTRY (IHC) 67
7.2.4 NEXT-GENERATION SEQUENCING (NGS) 69
7.2.5 MICROARRAYS 70
7.2.6 FLOW CYTOMETRY 71
7.2.7 OTHER TECHNOLOGIES 73
7.3 INSTRUMENT-BASED 74
7.3.1 DIAGNOSTIC IMAGING 74
7.3.1.1 Magnetic resonance imaging (MRI) 76
7.3.1.2 Computed tomography (CT) 77
7.3.1.3 Positron emission tomography (PET) 78
7.3.1.3.1 Standalone positron emission tomography 79
7.3.1.3.2 Hybrid positron emission tomography 80
7.3.1.4 Mammography 81
7.3.1.5 Ultrasound 81
7.3.2 BIOPSIES 82
8 CANCER DIAGNOSTICS MARKET, BY REGION 85
8.1 INTRODUCTION 86
8.2 NORTH AMERICA 86
8.2.1 U.S. 89
8.2.1.1 GOVERNMENT INITIATIVES 89
8.2.1.2 INCREASE IN CANCER INCIDENCE 90
8.2.2 CANADA 92
8.2.2.1 HIGH INCIDENCE OF CANCER 92
8.2.2.2 GOVERNMENT FUNDING 92
8.3 EUROPE 94
8.3.1 FUNDING FOR CANCER DIAGNOSTICS RESEARCH 95
8.3.2 EU-5 (U.K., GERMANY, FRANCE, ITALY, SPAIN) 97
8.3.2.1 STRONG GOVERNMENT SUPPORT 97
8.3.2.2 RESEARCH COLLABORATIONS 98
8.3.2.3 INCREASE IN DIAGNOSTIC IMAGING CENTERS 99
8.3.2.4 RISING PUBLIC AND PRIVATE INVESTMENTS 99
8.3.3 REST OF EUROPE (ROE) 101
8.3.3.1 AGING POPULATION 101
8.3.3.2 CONFERENCES BOOSTING AWARENESS 101
8.3.3.3 GOVERNMENT INVESTMENTS IN RUSSIA 102
?
8.4 ASIA 104
8.4.1 CHINA 107
8.4.1.1 EXPANSION OF INTERNATIONAL PLAYERS 107
8.4.1.2 AGING POPULATION AND INCREASING CANCER INCIDENCE 108
8.4.2 JAPAN 110
8.4.2.1 AGING POPULATION AND HIGH HEALTHCARE EXPENDITURE IN JAPAN 110
8.4.3 INDIA 112
8.4.3.1 INCREASING FOCUS OF INTERNATIONAL PLAYERS ON INDIA 112
8.4.4 REST OF ASIA 114
8.4.4.1 PRESENCE OF INTERNATIONAL PLAYERS BOOSTING MARKET GROWTH 114
8.5 REST OF THE WORLD (ROW) 116
8.5.1 GOVERNMENT INITIATIVES BOOSTING DEMAND FOR CANCER DIAGNOSTICS 117
8.5.2 AGING POPULATION, PRESENCE OF INTERNATIONAL PLAYERS 117
8.5.3 INCREASE IN CANCER INCIDENCES AND RISING GOVERNMENT EXPENDITURE 118
8.5.4 GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE 118
9 COMPETITIVE LANDSCAPE 121
9.1 MARKET SHARE ANALYSIS 121
9.2 COMPETITIVE LANDSCAPE: OVERVIEW 129
9.3 COMPETITIVE SITUATION AND TRENDS 131
9.3.1 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES 132
9.3.2 NEW PRODUCT LAUNCHES 133
9.3.3 ACQUISITIONS 134
9.3.4 EXPANSION 135
9.3.5 OTHERS 136
10 COMPANY PROFILES 137
10.1 INTRODUCTION 137
10.3 BECTON, DICKINSON AND COMPANY 142
10.3.1 BUSINESS OVERVIEW 142
10.3.2 PRODUCT PORTFOLIO 143
10.3.3 KEY STRATEGY 143
10.3.4 RECENT DEVELOPMENTS 144
10.4 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 145
10.4.1 BUSINESS OVERVIEW 145
10.4.2 PRODUCT PORTFOLIO 146
10.4.3 KEY STRATEGY 146
10.4.4 RECENT DEVELOPMENTS 147
?
10.5 ABBOTT LABORATORIES 148
10.5.1 BUSINESS OVERVIEW 148
10.5.2 PRODUCT PORTFOLIO 149
10.5.3 KEY STRATEGY 149
10.5.4 RECENT DEVELOPMENTS 149
10.6 ROCHE HOLDING AG 150
10.6.1 BUSINESS OVERVIEW 150
10.6.2 PRODUCT PORTFOLIO 151
10.6.3 KEY STRATEGY 151
10.6.4 RECENT DEVELOPMENTS 152
10.7 THERMO FISHER SCIENTIFIC, INC. 153
10.7.1 BUSINESS OVERVIEW 153
10.7.2 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 153
10.7.3 PRODUCT PORTFOLIO 154
10.7.4 KEY STRATEGY 154
10.7.5 RECENT DEVELOPMENTS 155
10.8 AGILENT TECHNOLOGIES, INC. 156
10.8.1 BUSINESS OVERVIEW 156
10.8.2 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 156
10.8.3 PRODUCT PORTFOLIO 157
10.8.4 KEY STRATEGY 157
10.8.5 RECENT DEVELOPMENTS 158
10.9 ILLUMINA, INC. 159
10.9.1 BUSINESS OVERVIEW 159
10.9.2 PRODUCT PORTFOLIO 160
10.9.3 KEY STRATEGY 160
10.9.4 RECENT DEVELOPMENTS 161
10.10 SIEMENS HEALTHCARE 162
10.10.1 BUSINESS OVERVIEW 162
10.10.2 PRODUCT PORTFOLIO 163
10.10.3 KEY STRATEGY 163
10.10.4 RECENT DEVELOPMENTS 164
10.11 C.R. BARD, INC. 165
10.11.1 BUSINESS OVERVIEW 165
10.11.2 PRODUCT PORTFOLIO 166
10.11.3 KEY STRATEGY 166
10.11.4 RECENT DEVELOPMENTS 166
?
11 APPENDIX 167
11.1 DISCUSSION GUIDE 167
11.2 COMPANY DEVELOPMENTS (2012-2015) 172
11.2.1 QIAGEN N.V. 172
11.2.2 BECTON, DICKINSON AND COMPANY 173
11.2.3 GE HEALTHCARE 173
11.2.4 ABBOTT LABORATORIES 174
11.2.5 ROCHE HOLDING AG 174
11.2.6 THERMO FISHER SCIENTIFIC, INC. 175
11.2.7 AGILENT TECHNOLOGIES, INC. 176
11.2.8 ILLUMINA, INC. 177
11.2.9 SIEMENS HEALTHCARE 177
11.3 AVAILABLE CUSTOMIZATIONS 178
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 178
11.5 RELATED REPORTS 180


LIST OF TABLES

TABLE 1 RISING PREVALENCE OF CANCER IS DRIVING THE GROWTH OF THE CANCER DIAGNOSTICS MARKET 41
TABLE 2 HIGH CAPITAL INVESTMENT RESTRAINING THE GROWTH OF CANCER DIAGNOSTICS MARKET 45
TABLE 3 EMERGING MARKETS PRESENT AN ARRAY OF OPPORTUNITIES FOR THE GROWTH OF THE CANCER DIAGNOSTICS MARKET 48
TABLE 4 STRINGENT REGULATORY GUIDELINES ARE A MAJOR CHALLENGE IN THE CANCER DIAGNOSTICS MARKET 51
TABLE 5 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 54
TABLE 6 CANCER DIAGNOSTICS MARKET SIZE FOR BREAST CANCER, BY REGION,
2013-2020 ($MILLION) 55
TABLE 7 CANCER DIAGNOSTICS MARKET SIZE FOR LUNG CANCER, BY REGION,
2013-2020 ($MILLION) 57
TABLE 8 CANCER DIAGNOSTICS MARKET SIZE FOR COLORECTAL CANCER, BY REGION, 2013-2020 ($MILLION) 58
TABLE 9 CANCER DIAGNOSTICS MARKET SIZE FOR MELANOMA, BY REGION,
2013-2020 ($MILLION) 58
TABLE 10 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER CANCERS, BY REGION,
2013-2020 ($MILLION) 60
TABLE 11 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2013-2020 ($MILLION) 62
TABLE 12 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2013-2020 ($MILLION) 63
TABLE 13 CANCER DIAGNOSTICS MARKET SIZE FOR PLATFORM-BASED DIAGNOSTICS,
BY REGION, 2013-2020 ($MILLION) 64
TABLE 14 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY REGION,
2013-2020 ($MILLION) 65
TABLE 15 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR PCR, BY APPLICATION,
2013-2020 ($MILLION) 65
TABLE 16 CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY REGION, 2013-2020 ($MILLION) 66
TABLE 17 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION,
BY APPLICATION, 2013-2020 ($MILLION) 67
TABLE 18 CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2013-2020 ($MILLION) 68
TABLE 19 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY,
BY APPLICATION, 2013-2020 ($MILLION) 68
TABLE 20 CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY REGION,
2013-2020 ($MILLION) 69
TABLE 21 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR NGS, BY APPLICATION,
2013-2020 ($MILLION) 70
TABLE 22 CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY REGION,
2013-2020 ($MILLION) 71
TABLE 23 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR MICROARRAYS,
BY APPLICATION, 2013-2020 ($MILLION) 71
TABLE 24 CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY, BY REGION,
2013-2020 ($MILLION) 72
TABLE 25 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR FLOW CYTOMETRY,
BY APPLICATION, 2013-2020 ($MILLION) 72
TABLE 26 CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2013-2020 ($MILLION) 73
TABLE 27 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES,
BY APPLICATION, 2013-2020 ($MILLION) 73
TABLE 28 GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2013-2020 ($MILLION) 74
TABLE 29 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY PRODUCT, 2013-2020 ($MILLION) 74
TABLE 30 CANCER DIAGNOSTICS MARKET SIZE FOR DIAGNOSTIC IMAGING, BY REGION, 2013-2020 ($MILLION) 75
TABLE 31 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR IMAGING, BY APPLICATION, 2013-2020 ($MILLION) 75
TABLE 32 CANCER DIAGNOSTICS MARKET SIZE FOR MRI, BY REGION,
2013-2020 ($MILLION) 77
TABLE 33 CANCER DIAGNOSTICS MARKET SIZE FOR CT, BY REGION, 2013-2020 ($MILLION) 78
TABLE 34 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY PRODUCT,
2013-2020 ($MILLION) 78
TABLE 35 CANCER DIAGNOSTICS MARKET SIZE FOR PET, BY REGION,
2013-2020 ($MILLION) 79
TABLE 36 CANCER DIAGNOSTICS MARKET SIZE FOR STANDALONE PET, BY REGION,
2013-2020 ($MILLION) 79
TABLE 37 CANCER DIAGNOSTICS MARKET SIZE FOR HYBRID PET, BY REGION,
2013-2020 ($MILLION) 80
TABLE 38 CANCER DIAGNOSTICS MARKET SIZE FOR MAMMOGRAPHY, BY REGION,
2013-2020 ($MILLION) 81
TABLE 39 CANCER DIAGNOSTICS MARKET SIZE FOR ULTRASOUND, BY REGION,
2013-2020 ($MILLION) 82
TABLE 40 CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY REGION,
2013-2020 ($MILLION) 83
TABLE 41 GLOBAL CANCER DIAGNOSTICS MARKET SIZE FOR BIOPSY, BY APPLICATION, 2013-2020 ($MILLION) 84
TABLE 42 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY,
2013—2020 ($MILLION) 87
TABLE 43 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 87
TABLE 44 NORTH AMERICA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET,
BY TECHNOLOGY, 2013—2020 ($MILLION) 88
TABLE 45 NORTH AMERICA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET,
BY TECHNOLOGY, 2013—2020 ($MILLION) 88
TABLE 46 NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2013—2020 ($MILLION) 89
TABLE 47 U.S.: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 90
TABLE 48 U.S.: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 91
TABLE 49 U.S.: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 91
TABLE 50 CANADA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 92
TABLE 51 CANADA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 93
TABLE 52 CANADA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 93
TABLE 53 EUROPE: CANCER DIAGNOSTICS MARKET, BY REGION, 2013—2020 ($MILLION) 95
TABLE 54 EUROPE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 95
TABLE 55 EUROPE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 96
TABLE 56 EUROPE: CANCER DIAGNOSTICS INSTRUMENT MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 96
TABLE 57 EUROPE: CANCER DIAGNOSTICS MARKET, BY APPLICATION,
2013—2020 ($MILLION) 97
TABLE 58 EU-5: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 100
TABLE 59 EU-5: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 100
TABLE 60 EU-5: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 101
TABLE 61 ROE: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 102
TABLE 62 ROE: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 103
TABLE 63 ROE: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 103
TABLE 64 ASIA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2013—2020 ($MILLION) 105
TABLE 65 ASIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 105
TABLE 66 ASIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 106
TABLE 67 ASIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 106
TABLE 68 ASIA: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION) 107
TABLE 69 CHINA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 108
TABLE 70 CHINA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 109
TABLE 71 CHINA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 109
TABLE 72 JAPAN: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY,
2013—2020 ($MILLION) 110
TABLE 73 JAPAN: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 111
TABLE 74 JAPAN: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 111
TABLE 75 INDIA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 113
TABLE 76 INDIA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 113
TABLE 77 INDIA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 114
TABLE 78 ROA: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 114
TABLE 79 ROA: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 115
TABLE 80 ROA: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 115
TABLE 81 ROW: CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 119
TABLE 82 ROW: CANCER DIAGNOSTICS PLATFORM-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 119
TABLE 83 ROW: CANCER DIAGNOSTICS INSTRUMENT-BASED MARKET, BY TECHNOLOGY, 2013—2020 ($MILLION) 120
TABLE 84 ROW: CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2013—2020 ($MILLION) 120
TABLE 85 COLLABORATIONS/AGREEMENTS/PARTNERSHIPS/ALLIANCES, 2012-2015 132
TABLE 86 NEW PRODUCT LAUNCHES, 2012-2015 133
TABLE 87 ACQUISITIONS, 2012-2015 134
TABLE 88 EXPANSIONS, 2012-2015 135
TABLE 89 OTHER STRATEGIES, 2012-2015 136


LIST OF FIGURES

FIGURE 1 CANCER DIAGNOSTICS MARKET SEGMENTATION 19
FIGURE 2 GLOBAL CANCER DIAGNOSTICS MARKET : RESEARCH METHODOLOGY STEPS 22
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 27
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
FIGURE 7 PLATFORM-BASED DIAGNOSTICS TO WITNESS HIGHEST CAGR OF 24.8% FROM 2015 TO 2020 30
FIGURE 8 GLOBAL PLATFORM-BASED CANCER DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2015-2020 31
FIGURE 9 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 32
FIGURE 10 LARGEST AND FASTEST-GROWING CANCER DIAGNOSTIC APPLICATIONS,
2015-2020 33
FIGURE 11 CANCER DIAGNOSTICS MARKET LIKELY TO GROW AT A CAGR OF 12.9% IN THE FORECAST PERIOD 34
FIGURE 12 CANCER DIAGNOSTICS MARKET, BY REGION AND APPLICATION: NORTH AMERICA WILL DOMINATE THE CANCER DIAGNOSTICS MARKET IN 2015 35
FIGURE 13 ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 36
FIGURE 14 PLATFORM-BASED TECHNOLOGY LIKELY TO GAIN SIGNIFICANT MARKET SHARE
BY 2020 36
FIGURE 15 CANCER DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, and CHALLENGES 38
FIGURE 16 MARKET GROWTH WILL BE DRIVEN BY RISING INCIDENCE and PREVALENCE OF BREAST AND LUNG CANCERS 53
FIGURE 17 LUNG CANCER APPLICATION IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 54
FIGURE 18 NGS, A GROUND-BREAKING TECHNOLOGY IN CANCER DIAGNOSIS 62
FIGURE 19 ULTRASOUND ACCOUNTED FOR THE LARGEST SHARE OF THE CANCER DIAGNOSTICS MARKET FOR IMAGING 76
FIGURE 20 GLOBAL NGS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014 121
FIGURE 21 GLOBAL MICROARRAYS MARKET (FOR CANCER DIAGNOSTICS) SHARE ANALYSIS, BY KEY PLAYER, 2014 122
FIGURE 22 GLOBAL FLOW CYTOMETRY (FOR CANCER DIAGNOSTICS) MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 123
FIGURE 23 GLOBAL MRI IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 124
FIGURE 24 GLOBAL CT IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 125
FIGURE 25 GLOBAL PET IMAGING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 126
FIGURE 26 GLOBAL ULTRASOUND IMAGING MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2014 127
FIGURE 27 AGILENT TECHNOLOGIES AND QIAGEN WERE THE MOST AGGRESSIVE PLAYERS 129
FIGURE 28 NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY FOR MARKET PLAYERS 130
FIGURE 29 BATTLE FOR MARKET SHARE: COLLABORATIONS/AGREEMENTS/ PARTNERSHIPS/ ALLIANCES WERE KEY STRATEGIES 131
FIGURE 30 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET 137
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT 138
FIGURE 32 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 142
FIGURE 33 GE HEALTHCARE: COMPANY SNAPSHOT 145
FIGURE 34 ABBOTT: COMPANY SNAPSHOT 148
FIGURE 35 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 150
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT 159
FIGURE 37 SIEMENS: COMPANY SNAPSHOT 162
FIGURE 38 C.R. BARD, INC.: COMPANY SNAPSHOT 165

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.